Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29042594 | 0.80 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL29579310 | 0.79 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL31252311 | 0.78 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL30308398 | 0.78 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL16267050 | 0.78 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL25259886 | 0.77 | DPP4 (0.31) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL21723903 | 0.76 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL22320712 | 0.76 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL1821813 | 0.76 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2TSHR | |
| SCHEMBL16655509 | 0.76 | DPP4 (0.45) | GABRA1GABRG2GABRB3GABRB2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415813-B2 | Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2025-09-16 | — | — | US | claimed |
| US-20250136539-A1 | ESTERS OF 5-METHYLHEX-2-ENOL AND THEIR USE AS AROMA CHEMICALS | BASF SE (DE) | 2025-05-01 | — | — | US | claimed |
| US-20230416178-A1 | FORMATION OF P-ALKYLPHENOLS BASED ON INTERMOLECULAR REACTION OF ETHYNE WITH 2-ALKYLFURANS IN THE PRESENCE OF GOLD(I) COMPLEXES | DSM IP ASSETS B.V. (NL) | 2023-12-28 | — | — | US | claimed |
| WO-2022096701-A1 | FORMATION OF P-ALKYLPHENOLS BASED ON INTERMOLECULAR REACTION OF ETHYNE WITH 2-ALKYLFURANS IN THE PRESENCE OF GOLD(I) COMPLEXES | DSM IP ASSETS B.V. (NL) | 2022-05-12 | — | — | WO | claimed |
| US-20210332063-A1 | METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KP) | 2021-10-28 | — | — | US | claimed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12415813-B2 | Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (KR) | 2025-09-16 | — | — | US | disclosed |
| US-20250136539-A1 | ESTERS OF 5-METHYLHEX-2-ENOL AND THEIR USE AS AROMA CHEMICALS | BASF SE (DE) | 2025-05-01 | — | — | US | disclosed |
| US-20250057959-A1 | PHOSPHANE GOLD(I)-N-HETEROCYCLIC CARBENE COMPLEXES FOR TREATING CANCER | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-02-20 | — | — | US | disclosed |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| EP-3835284-B1 | INTERMOLECULAR REACTION OF PROPARGYL ETHERS WITH DIMETHYLFURAN IN THE PRESENCE OF GOLD(I) COMPLEXES | DSM IP ASSETS BV (NL) | 2024-09-25 | — | — | EP | disclosed |
| EP-3394020-A1 | INTERMOLECULAR REACTION OF PROPARGYL ETHERS WITH DIMETHYLFURAN IN THE PRESENCE OF GOLD(I) COMPLEXES | DSM IP Assets B.V. (NL) | 2018-10-31 | — | — | EP | disclosed |
| US-20170318682-A1 | METHOD OF MANUFACTURING A HYBRID METAL PATTERN BY USING WIRE EXPLOSION AND LIGHT-SINTERING, AND A HYBRID METAL PATTERN MANUFACTURED THEREBY | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) | 2017-11-02 | — | — | US | disclosed |
| WO-2017108339-A1 | INTERMOLECULAR REACTION OF PROPARGYL ETHERS WITH DIMETHYLFURAN IN THE PRESENCE OF GOLD(I) COMPLEXES | DSM IP ASSETS B.V. (NL) | 2017-06-29 | — | — | WO | disclosed |
| US-9573967-B2 | N-heterocyclic carbene gold complexes with anticancer properties and methods of use thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2017-02-21 | — | — | US | disclosed |
| US-20160326187-A1 | N-HETEROCYCLIC CARBENE GOLD COMPLEXES WITH ANTICANCER PROPERTIES AND METHODS OF USE THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2016-11-10 | — | — | US | disclosed |
| CN-103483349-B | Synthesis method for Cladiellin natural products Pachycladin D with important biological activity | UNIV PEKING SHENZHEN GRAD SCHO | 2015-05-13 | — | — | CN | disclosed |
| CN-103483349-A | Synthesis method for Cladiellin natural products Pachycladin D with important biological activity | UNIV PEKING SHENZHEN GRAD SCHO | 2014-01-01 | — | — | CN | disclosed |
| US-7767841-B1 | Gold complexes for catalysIS and preparation thereof | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION, INC. (US) | 2010-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136539-A1 | ESTERS OF 5-METHYLHEX-2-ENOL AND THEIR USE AS AROMA CHEMICALS | ENY2, SCD5, NOTUM | GABRA1 3248/4885GABRG2 4265/4885GABRB3 3139/4885 |
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | GABRA1 4396/4885GABRG2 4046/4885GABRB3 4444/4885 |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | GABRA1 3925/4885GABRG2 3355/4885GABRB3 3466/4885 |
| US-20210332063-A1 | METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR | FARS2, CYP4F11, CYP4B1 | GABRA1 478/4885GABRG2 1181/4885GABRB3 806/4885 |
| US-20160326187-A1 | N-HETEROCYCLIC CARBENE GOLD COMPLEXES WITH ANTICANCER PROPERTIES AND METHODS OF USE THEREOF | MCL1, HCCS, ACIN1 | GABRA1 2074/4885GABRG2 2765/4885GABRB3 1989/4885 |
| US-12415813-B2 | Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor | FARS2, CYP4F11, CYP4B1 | GABRA1 478/4885GABRG2 1181/4885GABRB3 806/4885 |
| US-20230416178-A1 | FORMATION OF P-ALKYLPHENOLS BASED ON INTERMOLECULAR REACTION OF ETHYNE WITH 2-ALKYLFURANS IN THE PRESENCE OF GOLD(I) COMPLEXES | EP300, CYP2J2, AHR | GABRA1 3397/4885GABRG2 2994/4885GABRB3 3296/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | GABRA1 3925/4885GABRG2 3355/4885GABRB3 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.